Research development in surivin protein on anti-cancer therapies

Abstract

Abstract: Survivin is a cancer-specific protein, and it upregulated in almost all human tumors. Because of its upregulation in malignancy and its key role in apoptosis, proliferation and angiogenesis, survivin is considered as a new target for anti-cancer therapies. Strategies under the research to target survivin include antisense oligonucleotides, siRNA, ribozymes, immunotherapy and small molecular weight molecules. Several phase I/II clinical trials targeting survivin are currently ongoing. The usage of survivin antagonists combined with conventional therapies might achieve better therapeutic effect.

Key words: survivin, anti-cancer, therapy, apoptosis

CLC Number:

R73
R966

CHU Ji-ru, XIE Hai-tang, LI Juan, ZHONG Zheng-ling. Research development in surivin protein on anti-cancer therapies[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(7): 835-840.

References

[1] Srinivasula SM, Ashwell JD.IAPs: what's in a name[J]? Mol Cell, 2008, 30(2): 123-135.
[2] Jeyaprakash AA, Klein UR, Lindner D, et al.Structure of a survivin-borealin-INCENP core complex reveals how chromosomal passengers travel together[J]. Cell, 2007, 131(2): 271-285.
[3] Guha M, Altieri DC.Survivin as a global target of intrinsic tumor suppression networks[J]. Cell Cycle, 2009, 8(17): 2708-2710.
[4] Altieri DC.Survivin, cancer networks and pathway-directed drug discovery[J]. Nat Rev Cancer, 2008, 8(1): 61-70.
[5] Mita AC, Mita MM, Nawrocki ST, et al.Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics[J]. Clin Cancer Res, 2008, 14(16): 5000-5005.
[6] Ruchaud S, Carmena M, Earnshaw WC, et al.Chromosomal passengers: conducting cell division[J]. Nat Rev Mol Cell Biol, 2007, 8(10): 798-812.
[7] Sampath SC, Ohi R, Leismann O, et al.The chromosomal passenger complex is required for chromatininduced microtubule stabilization and spindle assembly[J]. Cell, 2004, 118(2): 187-202.
[8] Rosa J, Canovas P, Islam A, et al.Survivin modulates microtubule dynamics and nucleation throughout the cell cycle[J]. Mol Biol Cell, 2006, 17(3): 1483-1493.
[9] Sandall S, Severin F, McLeod IX, et al. A Bir1-Sli15 complex connects centromeres to microtubules and is required to sense kinetochore tension[J]. Cell, 2006, 127(6): 1179-1191.
[10] Lens SM, Vader G, Medema RH.The case for survivin as mitotic regulator[J]. Curr Opin Cell Biol, 2006, 18(6): 616-622.
[11] Dohi T, Xia F, Altieri DC.Compartmentalized phosphorylation of IAP by protein kinase A regulates cytoprotection[J]. Mol Cell, 2007, 27(1): 17-28.
[12] Kang BH, Altieri DC.Regulation of survivin stability by the aryl hydrocarbon receptor-interacting protein[J]. J Biol Chem, 2006, 281(34): 24721-24727.
[13] Ghosh JC, Dohi T, Kang BH, et al.Hsp60 regulation of tumor cell apoptosis[J]. J Biol Chem, 2008, 283(8): 5188-5194.
[14] Fortugno P, Beltrami E, Plescia J, et al.Regulation of survivin function by Hsp90[J]. Proc Natl Acad Sci USA, 2003, 100(12): 13791-13796.
[15] Paik S, Shak S, Tang G, et al.A multigene assay to predict recurrence of tamoxifen-treated, nodenegative breast cancer[J]. N Engl J Med, 2004, 351(27): 2817-2826.
[16] van der Greef J, McBurney RN. Innovation: rescuing drug discovery: in vivo systems pathology and systems pharmacology[J]. Nat Rev Drug Discovery, 2005, 4(12): 961-967.
[17] Li F, Ackermann EJ, Bennett CF, et al.Pleiotropic cell-division defects and apoptosis induced by interference with survivin function[J]. Nat Cell Biol, 1999, 1(8): 461-466.
[18] Molckovsky A, Siu LL.First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American Society of Clinical Oncology meeting[J]. J Hematol Oncol, 2008, 1: 20.
[19] Hansen JB, Fisker N, Westergaard M, et al.SPC3042: a proapoptotic survivin inhibitor[J]. Mol Cancer Ther, 2008, 7(9): 2736-2745.
[20] Walker K, Padhiar M.AACR-NCI-EORTC-21st international symposium. Molecular targets and cancer therapeutics - Part 1[J]. IDrugs, 2010, 13(1): 7-9.
[21] Mobahat M, Narendran A, Riabowol K.Survivin as a preferential target for cancer therapy[J]. Int J Mol Sci, 2014, 15(2): 2494-2451.
[22] Davis ME, Zuckerman JE, Choi CHJ, et al.Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles[J]. Nature, 2010, 464(7291): 1067-1070.
[23] Nakahara T, Takeuchi M, Kinoyama I, et al.YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts[J]. Cancer Res, 2007, 67(17): 8014-8021.
[24] Tolcher AW, Mita A, Lewis LD, et al.Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of surviving[J]. J Clin Oncol, 2008, 26(32): 5198-5203.
[25] Satoh T, Okamoto I, Miyazaki M, et al.Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors[J]. Clin Cancer Res, 2009, 15(11): 3872-3880.
[26] Giaccone G, Zatloukal P, Roubec J, et al.Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer[J]. J Clin Oncol, 2009, 27(27): 4481-4486.
[27] Lewis KD, Samlowski W, Ward J, et al.A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma[J]. Invest New Drugs, 2011, 29(1): 161-166.
[28] Chang CC, Heller JD, Kuo J, et al.Tetra-O-methyl nordihydroguaiaretic acid induces growth arrest and cellular apoptosis by inhibiting Cdc2 and survivin expression[J]. Proc Natl Acad Sci USA, 2004, 101(36): 13239-13244.
[29] Smolewski P.Terameprocol, a novel site-specific transcription inhibitor with anticancer activity[J]. IDrugs, 2008, 11(3): 204-214.
[30] Park R, Chang CC, Liang YC, et al.Systemic treatment with tetra-O-methyl nordihydroguaiaretic acid suppresses the growth of human xenograft tumors[J]. Clin Cancer Res, 2005, 11(12): 4601-4609.
[31] Zhu X, Ma Y, Liu D.Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights[J]. J Hematol Oncol, 2010, 3: 17.
[32] Khanna N, Dalby R, Connor A, et al.Phase I clinical trial of repeat dose terameprocol vaginal ointment in healthy female volunteers[J]. Sex Transm Dis, 2008, 35(6): 577-582.
[33] Khanna N, Dalby R, Tan M, et al.Phase I/II clinical safety studies of terameprocol vaginal ointment[J]. Gynecol Oncol, 2007, 107(3): 554-562.
[34] Andersen MH, Sorensen RB, Schrama D, et al.Cancer treatment: the combination of vaccination with other therapies[J]. Cancer Immunol Immunother, 2008, 57(11): 1735-1743.
[35] Rohayem J, Diestelkoetter P, Weigle B, et al.Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients[J]. Cancer Res, 2000, 60(7): 1815-1817.
[36] Schmidt SM, Schag K, Muller MR, et al.Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells[J]. Blood, 2003, 102(2): 571-576.
[37] Casati C, Dalerba P, Rivoltini L, et al.The apoptosis inhibitor protein survivin induces tumor-specific C<inline-formula><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="Mml1-1009-2501-19-7-835"><mml:msup><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">D</mml:mi></mml:mrow><mml:mrow><mml:mn>8</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msup></mml:math></inline-formula> and C<inline-formula><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="Mml2-1009-2501-19-7-835"><mml:msup><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">D</mml:mi></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msup></mml:math></inline-formula> T cells in colorectal cancer patients[J]. Cancer Res, 2003, 63(15): 4507-4515.
[38] Idenoue S, Hirohashi Y, Torigoe T, et al.A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins[J]. Clin Cancer Res, 2005, 11(4): 1474-1482.
[38] Schmitz M, Diestelkoetter P, Weigle B, et al.Generation of survivin-specific C<inline-formula><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="Mml3-1009-2501-19-7-835"><mml:msup><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">D</mml:mi></mml:mrow><mml:mrow><mml:mn>8</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msup></mml:math></inline-formula> T effector cells by dendritic cells pulsed with protein or selected peptides[J]. Cancer Res, 2000, 60(17): 4845-4849.
[40] Pisarev V, Yu B, Salup R, et al.Full-length dominant-negative survivin for cancer immunotherapy[J]. Clin Cancer Res, 2003, 9(17): 6523-6533.
[41] Siegel A, Wagner N, Schmitz M.Induction of antitumour immunity using survivin peptide-pulsed dendritic cells in a murine lymphoma model[J]. Br J Haematol, 2003, 122(6): 911-914.
[42] Friedrichs B, Siegel S, Andersen MH, et al.Survivin-derived peptide epitopes and their role for induction of antitumor immunity in hematological malignancies[J]. Leuk Lymphoma, 2006, 47(6): 978-985.
[43] Trepiakas R, Berntsen A, Hadrup SR, et al.Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial[J]. Cytotherapy, 12(6): 721-734.
[44] Berntsen A, Trepiakas R, Wenandy L, et al.Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial[J]. J Immunother, 2008, 31(8): 771-780.
[45] Weide B, Pascolo S, Scheel B, et al.Direct injection of protamineprotected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients[J]. J Immunother, 2009, 32(5): 498-507.
[46] Fukuda S, Pelus LM.Survivin, a cancer target with an emerging role in normal adult tissues[J]. Mol Cancer Ther, 2006, 5(5): 1087-1098.
[47] Blum B, Bar-Nur O, Golan-Lev T, et al.The anti-apoptotic gene survivin contributes to teratoma formation by human embryonic stem cells[J]. Nat Biotechnol, 2009, 27(3): 281-287.
[48] O'Connor DS, Wall NR, Porter AC. A p34 (cdc2) survival checkpoint in cancer[J]. Cancer Cell, 2002, 2(1): 43-54.
[49] Lee CW, Raskett CM, Prudovsky I.Molecular dependence of estrogen receptor-negative breast cancer on a notch-survivin signaling axis[J]. Cancer Res, 2008, 68(13): 5273-5281.
[50] Kim PJ, Plescia J, Clevers H, et al.Survivin and molecular pathogenesis of colorectal cancer[J]. Lancet, 2003, 362(9379): 205-209.
[51] Ferrari G, Terushkin V, Wolff MJ, et al.TGF-β1 induces endothelial cell apoptosis by shifting VEGF activation of p38(MAPK) from the prosurvival p38β to proapoptotic p38α[J]. Mol Cancer Res, 2012, 10(5): 605-614.
[52] Daly C, Wong V, Burova E, et al.Angiopoietin-1 modulates endothelial cell function and gene expression via the transcription factor FKHR (FOXO1)[J]. Genes Dev, 2004, 18(9): 1060-1071.
[53] Tran J, Master Z, Yu JL, et al.A role for survivin in chemoresistance of endothelial cells mediated by VEGF[J]. Proc Natl Acad Sci USA, 2002, 99(7): 4349-4354.
[54] Lessene G, Czabotar PE, Colman PM.BCL-2 family antagonists for cancer therapy[J]. Proc Natl Acad Sci USA, 2014, 111(15): 5682-5687.
[55] Plescia J, Salz W, Xia F, et al.Rational design of shepherdin, a novel anticancer agent[J]. Cancer Cell, 2005, 7(5): 457-468.